New Targeted Therapy for Myelodysplastic Syndromes
The FDA has approved the IDH1 inhibitor ivosidenib for a group of blood cancers harboring an IDH1 mutation. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of relapsed...